Publications
138
Citations
4,332
Est. group size
—
Recurring co-author estimate
Active years
51
Publishing since 1976
Maria C. Bell conducts clinical and translational research in gynecologic oncology, focusing on treatments for ovarian, endometrial, and cervical cancers. Much of the work involves clinical trials of new therapies, including immunotherapy, gene therapy (such as IL-12), and targeted drugs, as well as laboratory studies of tumor biology and drug targets. There is also attention to improving patient access to clinical trials in rural settings.
Publication activity grew over the decade with a pronounced peak in 2023 and steady output in recent years, averaging about 8.6 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
Gynecologic Oncology · 2025
- A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
Journal of Clinical Oncology · 2025
- 105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)
ESMO Open · 2025
- Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology · 2025
- Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Corrigendum to “OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer” [Gynecol Oncol 2025 Jun 197 182–191]
Gynecologic Oncology · 2025
- VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY
International Journal of Gynecological Cancer · 2025
- Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Journal of Clinical Oncology · 2024
- Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Journal of Clinical Oncology · 2024
- Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal of Clinical Oncology · 2024
- Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy
Journal of Ovarian Research · 2024
- Abstract CT267: Temsirolimus (T) in patients (pts) with solid tumors with <i>AKT1/3</i> amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Cancer Research · 2024
- Functional neuronal circuits promote disease progression in cancer
Science Advances · 2023
- Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report
Gynecologic Oncology · 2023
- Synthesis and Antitumor Activity of Brominated-Ormeloxifene (Br-ORM) against Cervical Cancer
ACS Omega · 2023
- Journal of Clinical Oncology×10
- Journal of the American Academy of Dermatology×4
- Gynecologic Oncology×3
- International Journal of Gynecological Cancer×3
- Cancer Research×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile